AIRNA
edits the message,
not the master copy.

By the YesPress Desk · Filed from Cambridge, Massachusetts

Most genetic diseases come down to something almost absurdly small: a single letter, in a code three billion letters long, sitting in the wrong place. For decades the dream of genetic medicine has been to reach into a patient's cells and correct that letter. Tools like CRISPR do it by editing DNA - permanently. AIRNA is built on a different bet. Instead of rewriting the master copy, it edits the working copy: the RNA.

RNA is the transient message a cell reads to build a protein. Edit the RNA and you change the protein - but only for as long as that message exists. The correction fades unless you re-dose. To some, that sounds like a limitation. To AIRNA, it is the point. A change you can walk back is a change you can control.

The company, headquartered in Cambridge, Massachusetts with research roots in Tubingen, Germany, does not manufacture a new molecular scissor. It recruits one that already lives in every human cell - an enzyme called ADAR (adenosine deaminase acting on RNA). ADAR's day job is to chemically convert one RNA letter, adenosine (A), into inosine (I), which the cell reads as guanosine (G). AIRNA designs short strands of genetic material, called oligonucleotides, that act like a homing beacon: they bind to a chosen spot on a target RNA and summon ADAR to make exactly the edit AIRNA wants, and nowhere else.

AIRNA's first target is alpha-1 antitrypsin deficiency, or AATD - an inherited condition that can damage the lungs and liver. Its most common severe form traces to a mutation called PiZ: a spot where a single adenosine sits where a guanosine belongs. That one-letter error garbles a protein the body needs to protect its tissues.

AIRNA's lead candidate, AIR-001, is designed to correct that exact letter at the RNA level. In preclinical studies it demonstrated up to 59% precise RNA editing in vivo - a figure that helped move the program out of the lab and into a Phase 1/2 clinical trial. Because AATD is caused by a well-defined genetic glitch with no cure, it is a natural proving ground for a platform whose whole premise is single-letter precision.

Behind AIR-001 sits a pipeline the company intends to push beyond rare disease, into common cardiometabolic and other conditions - the wider arena where an RNA-editing approach could, in principle, reach far more patients.